Inflation? It's not sticky at all
STOXX Europe 600 down 0.7%
Healthcare drags; ArgenX plunges
Rolls-Royce eyes profitability boost
S&P 500 futures down
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at firstname.lastname@example.org
INFLATION? IT'S NOT STICKY AT ALL (1010 GMT)
Several market participants worry that inflation could run persistently above central banks' 2% target, meaning rates will have to stay high for a long time.
Stephen Jen, chief executive officer at Eurizon SLJ Capital, disagrees. He sees a quick decline in consumer price dynamics and a steady state below pre-pandemic levels.
"The chart below shows the rapid rate with which inflation has declined in these two jurisdictions (U.S. and euro area), making the rise and the fall in inflation quite symmetric, contrary to the popular opinion that the fall in inflation would be much slower than its rise," he says.
"In the long run, we see the new steady-state inflation being only marginally higher than the lows witnessed before the Pandemic," he adds. "The structural drivers of inflation – demographics, globalisation, trade, and the energy transition – seem to point to lower inflation, not higher inflation."
According to Jen, who previously headed up currency research at Morgan Stanley, de-globalisation will not fuel inflation, as it is far from clear that the industrial capacity divested from China would end up in higher-cost jurisdictions. Neither will the green transition as prices of most critical equipment are plummeting because the supply has run ahead of demand.
Last but not least, artificial intelligence (AI) will be disinflationary and productivity-enhancing, like previous technological innovations, Jen says.
STOXX LOWER, HEALTHCARE DRAGS, ROLLS ROYCE SHINES (0916 GMT)
European equities were off to a weak start onTuesday with the region-wide STOXX 600 .STOXX falling 0.6% as the healthcare .SXDP sector led declines, down 1.3%.
Drugmaker Novo Nordisk NOVOb.CO and luxury group LVMH LVMH.PA, Europe's two most valuable companies, were the biggest negative weights, both falling over 2% in early trading.
ArgenX ARGX.BR followed with a 16% slide after its VYVGART Hytrulo drug failed to meet primary and secondary endpoints in a study for the treatment of an autoimmune disorder.
Losses were contained but broad based. Insurers .SXIP and banks .SX7P outperformed, moving around parity.
Rolls-Royce RR.L was a bright spot. Its shares rose 6%, bringing YTD gains to 170%, as investors welcomed the British engineer's to become a much more profitable business with a goal to boost civil aerospace margins to 15-17% from 2.5%.
EUROPE SET FOR WEAKER START (0747 GMT)
European shares were set for a weaker start on Tuesday, as traders consolidate November gains that have set the region wide STOXX 600 .STOXX for its best month since January, up over 5%.
Investors have been covering short positions, encouraged by easing inflation pressures that have bolstered bets that the Fed and the ECB have finished with rate hikes and could possibly cut borrowing costs at some point next year.
EuroSTOXX50 and FTSE futures fell 0.4 and 0.3% respectively following a lower close on Wall Street, although Asian shares rose slightly, as investors looked ahead to a crucial U.S. inflation report later this week. S&P 500 futures dipped 0.2%.
Corporate news in Europe was thinning out as the holiday shopping season kicked into gear. Data on Monday showed British shopper numbers and transactions edged lower on Black Friday versus last year.
Like-for-like retail growth at Pets at Home PETSP.L was about 4% in the early weeks of Q3, as Britons gear up for the Christmas season and spend on their furry friends.
Still in the UK, Rolls Royce RR.L vowed to deliver up to 2.8 billion pounds of operating profit in the medium term by increasing the margin on its civil aerospace business.
EasyJet EZJ.L reported 2023 earnings in line with analyst expectations after a year of robust travel demand and forward bookings, but the low-cost British carrier said geopolitical instability would weigh on results in the current quarter.
In Brussels, drugmaker Argenx ARGX.BR was set for a big fall at the open on news that an ADVANCE-SC study of its Vyvgart Hytrulo drug - did not meet primary or secondary endpoints. A convertible bond could put pressure on video game producer Ubisoft UBIP.PA
Broker decisions could also drive price action. Continental CONG.DE rose 1.7% on Tradegate after Berenberg upgraded the stock to buy and Infineon IFXGn.DE was also higher after a Jefferies upgrade to buy. DB cut ING INGA.AS to hold and Julius Baer BAER.S was cut to underweight at Morgan Stanley.
CHINA'S SHEIN STEALS MARKET SPOTLIGHT(0656 GMT)
Asian markets kept up their November rally and the dollar dipped to three-month low, but big-name fast-fashion company Shein stole the market spotlight with an IPO filing that will likely test investor appetite for new listings.
Shein, known for its $10 tops and $5 biker shorts, filed confidentially for a U.S. IPO, sources told Reuters, with the China-founded and Singapore-based firm expected to go public sometime next year.
Whether this potential blockbuster gives a fillip to the lacklustre IPO market remains to be seen, after some high-profile public debuts this year failed to impress.
On a macro level, the theme remains the same: Traders are getting fidgety about whether the Fed is well and truly done with interest rate hikes, and when it is likely to start cutting rates - presumably next year.
The Fed's focus on beating inflation means Thursday's core personal consumption expenditures data, the central bank's preferred measure of inflation, will be the main event this week, with investors hesitant to place major bets and keeping share markets within a narrow range.
Risk appetite got a boost this month after data releases that hinted at easing inflation, stoking expectations that central banks had reached their interest rate peaks.
MSCI's broadest index of Asia-Pacific shares outside Japan .MIAPJ0000PUS is on course for its strongest monthly performance since January with a nearly 7% gain.
Japan's Nikkei, Asia's best-performing stock market this year, is set for its strongest monthly result in three years.
European stock markets are likely to see a subdued start to Tuesday, futures indicate, with a bare economic calendar leaving investors treading cautiously ahead of major economic data.
Meanwhile, British shopper numbers and transactions on Black Friday were lower than last year's, disappointing retailers looking for a pick-up in spending after a subdued October.
In contrast, U.S. spending online on Cyber Monday is set to exceed $12 billion, a record, according to preliminary estimates from Adobe Digital Insights, with price-conscious consumers favouring buy-now pay-later services to ease stress on their wallets.
Key developments that could influence markets on Tuesday:
France consumer confidence for November, Euro zone money M3 annual growth for October.
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.